5 / 5
Volume 2, Issue 4 (Suppl)
Breast Can Curr Res, an open access journal
Breast Pathology 2017
August 23-24, 2017
Page 40
conference
series
.com
August 23-24, 2017 Toronto, Canada
4
th
World Congress on
Breast Pathology and Cancer Diagnosis
Myron R Szewczuk, Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-007
Novel therapeutic target in multistage breast tumorigenesis
A
novel organizational signaling platform linked to glycosylated receptor tyrosine kinases (RTK) (e.g., EGFR, TrkA, insulin)
and TOLL-like (TLR) receptors is identified to regulate receptor activation process, all of which are known to play major
roles in tumorigenesis. This signaling paradigm proposes that ligand, binding to its receptor on the cell surface induces a
conformational change of the receptor, to initiate matrix metalloproteinase-9 (MMP-9) activation to induce neuraminidase-1
(Neu1). Activated Neu1 hydrolyzes α-2,3-sialyl residues linked to β-galactosides, which are distant from the ligand binding
sites. These ndings predict a pre-requisite desialylation process by activated Neu1 enabling the removal of steric hindrance
to receptor association. In addition, the relative levels of specific sialoglycan structures on the cell surface correlate with
the ability of cancer cells to form avascular 3D multicellular tumor spheroids and
in vivo
xenograft tumors. Here, we have
identified an innovative, promising and entirely new targeted therapy for cancer. Mammalian neuraminidase-1 (Neu1) in
complex with matrix metalloproteinase-9 and G-protein coupled receptor, tethered to RTKs and TLRs is identified as a major
target in the multi-stage of tumorigenesis. Pre-clinical studies support an entirely new cancer targeted therapy unaffected by
mutations of growth factor receptors, involved in tumor neovascularization, chemo-resistance of tumors, immune-mediated
tumorigenesis, and tissue invasion and metastasis.
Biography
Myron R Szewczuk is currently working as Professor of Immunology, Department of Biomedical and Molecular Sciences and Medicine of Queen’s University,
Kingston, Ontario, Canada for the past 36 years. He received his BSc in Chemistry (University of Guelph), MSc in Biochemistry (Guelph), PhD in Immunochemistry
(University of Windsor) and Post-doctoral training with Gregory Siskind, MD in Cellular Immunology at Cornell University Medical College, NYC. His recent research
has focused on the role of glycosylation in receptor activation with a particular focus on TOLL-like, nerve growth factor Trk, EGFR and insulin receptors. He has
discovered a novel receptor-signaling platform and its targeted translation in multi-stage of tumorigenesis.
szewczuk@queensu.caMyron R Szewczuk
Queen’s University, Canada
Notes: